Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8165365rdf:typepubmed:Citationlld:pubmed
pubmed-article:8165365lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0001655lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0005210lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8165365lifeskim:mentionsumls-concept:C0073994lld:lifeskim
pubmed-article:8165365pubmed:issue1lld:pubmed
pubmed-article:8165365pubmed:dateCreated1994-5-23lld:pubmed
pubmed-article:8165365pubmed:abstractTextWe investigated whether the anti-aversive effects of salmon calcitonin (SCT) was induced by increasing ACTH and beta-endorphin and/or by decreasing of prostaglandin E2 (PGE2) levels in plasma of mice to elucidate the mechanisms responsible for the analgesic effects of SCT. Intracerebroventricular (i.c.v.) injections of SCT inhibited acetic acid-induced aversive behavior (writhing) in a U-shaped dose response curve, the most effective dose being 0.1 IU/mouse. Intraperitoneal (i.p.) injections of acetic acid increased, but not significantly, the levels of plasma ACTH and PGE2, but not beta-endorphin, which are considered to be psychoneuroendocrines correlated with pain. SCT (0.1 IU/mouse, i.c.v.) significantly increased plasma ACTH levels (p < 0.05) and tended to increase beta-endorphin levels (p = 0.052) in acetic acid-treated mice, whereas no change in PGE2 level was observed (p > 0.1). These results suggest that the anti-aversive effects of SCT may be mediated, at least in part, by the activation of ACTH.lld:pubmed
pubmed-article:8165365pubmed:languageenglld:pubmed
pubmed-article:8165365pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:citationSubsetIMlld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8165365pubmed:statusMEDLINElld:pubmed
pubmed-article:8165365pubmed:monthJanlld:pubmed
pubmed-article:8165365pubmed:issn0034-5164lld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:FukuiSSlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:YamadaKKlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:UchidaKKlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:MaedaYYlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:HasegawaTTlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:NabeshimaTTlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:KawamataYYlld:pubmed
pubmed-article:8165365pubmed:authorpubmed-author:LuN MNMlld:pubmed
pubmed-article:8165365pubmed:issnTypePrintlld:pubmed
pubmed-article:8165365pubmed:volume83lld:pubmed
pubmed-article:8165365pubmed:ownerNLMlld:pubmed
pubmed-article:8165365pubmed:authorsCompleteYlld:pubmed
pubmed-article:8165365pubmed:pagination15-24lld:pubmed
pubmed-article:8165365pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:meshHeadingpubmed-meshheading:8165365-...lld:pubmed
pubmed-article:8165365pubmed:year1994lld:pubmed
pubmed-article:8165365pubmed:articleTitleRelationship between anti-aversive effects of salmon calcitonin and plasma levels of ACTH, beta-endorphin and prostaglandin E2 in mice.lld:pubmed
pubmed-article:8165365pubmed:affiliationDepartment of Neuropsychopharmacology, Nagoya University School of Medicine, Japan.lld:pubmed
pubmed-article:8165365pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8165365pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed